The estimated Net Worth of John Maraganore is at least $20 million dollars as of 20 May 2022. John Maraganore owns over 1,585 units of Alnylam Pharmaceuticals Inc stock worth over $7,864,633 and over the last 20 years he sold ALNY stock worth over $4,800,336. In addition, he makes $7,317,860 as Chief Executive Officer et Director at Alnylam Pharmaceuticals Inc.
John has made over 74 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 1,585 units of ALNY stock worth $415,127 on 20 May 2022.
The largest trade he's ever made was exercising 120,000 units of Alnylam Pharmaceuticals Inc stock on 16 June 2009 worth over $57,600. On average, John trades about 17,234 units every 49 days since 2004. As of 20 May 2022 he still owns at least 30,028 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of John Maraganore stock trades at the bottom of the page.
Dr. John M. Maraganore, Ph.D., is Chief Executive Officer, Director of the Alnylam Pharmaceuticals, Inc. Dr. Maraganore also served as our President from December 2002 to December 2007. From April 2000 to December 2002, Dr. Maraganore served as Senior Vice President, Strategic Product Development for Millennium Pharmaceuticals, Inc., a biopharmaceutical company (now a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited). He also serves as a director of Agios Pharmaceuticals, Inc. and Chair of the Biotechnology Industry Organization, a non-profit biotechnology trade organization. Dr. Maraganore formerly served as a director of bluebird bio, Inc. and Regulus Therapeutics Inc.
As the Chief Executive Officer et Director of Alnylam Pharmaceuticals Inc, the total compensation of John Maraganore at Alnylam Pharmaceuticals Inc is $7,317,860. There are no executives at Alnylam Pharmaceuticals Inc getting paid more.
John Maraganore is 57, he's been the Chief Executive Officer et Director of Alnylam Pharmaceuticals Inc since 2007. There are 15 older and 2 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
John's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal et Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: